Related Experiment Video
Updated: Jan 18, 2026
06:39
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
Published on: June 13, 2025
436
Sleep and circadian effects on the incretin system
Robin K Yuan1, Kirsi-Marja Zitting1
1Department of Medicine and Neurology, Division of Sleep and Circadian Disorders, Brigham and Women's Hospital and Division of Sleep Medicine, Harvard Medical School, Boston, MA 02115, USA.
Current Sleep Medicine Reports
|September 11, 2025
Summary
Sleep and circadian rhythms significantly influence incretin secretion, impacting metabolic health. Emerging research explores GLP-1/GIP-RA drugs for sleep disorders, highlighting a new frontier in metabolic and sleep medicine.
Area of Science:
- Endocrinology
- Sleep Medicine
- Metabolic Health
Background:
- Incretins like GLP-1 play a crucial role in metabolic regulation.
- Sleep and circadian rhythms are known modulators of metabolic outcomes.
- The interplay between incretins, sleep, and circadian rhythms is an emerging area of research.
Purpose of the Study:
- To review the current evidence on how sleep and circadian factors affect incretin secretion.
- To discuss the potential clinical applications of GLP-1/GIP-RA drugs in sleep medicine.
- To identify future research directions in this interdisciplinary field.
Main Methods:
- Systematic review of existing literature.
- Analysis of studies investigating incretin secretion in relation to sleep and circadian rhythms.
- Discussion of clinical trial data and FDA-approved therapies.
Main Results:
- GLP-1 secretion follows a circadian rhythm, which can be disrupted by diet, meal timing, and gut microbiota.
- Insufficient sleep and metabolic conditions like obesity and diabetes can blunt or alter incretin secretion patterns.
- GLP-1/GIP-RA drugs, such as tirzepatide, are being explored and approved for sleep-related conditions like obstructive sleep apnea.
Conclusions:
- Sleep and circadian rhythms demonstrably impact the incretin system.
- Further research is warranted to elucidate the complex interactions and optimize therapeutic strategies.
- Incretin-based therapies hold promise for managing metabolic and sleep disorders concurrently.
Related Concept Videos
02:19Circadian Rhythms and Gene Regulation
4.5K
The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent...
4.5K
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
354
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
354
01:24Glucagon-like Receptor Agonists
854
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
854
01:23Dipeptidyl Peptidase 4 Inhibitors
598
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
598
01:19Management of Insomnia
543
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
543
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K